December 29, 2015
Sanofi’s vaccines division gets Dengvaxia approval in Brazil
Sanofi Pasteur, the vaccines division of Sanofi, has gotten from Brayil regulatory approval to Dengvaxia. As the company said Monday ,…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
November 30, 2015
India progresses towards polio-free world
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”
November 27, 2015
Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal – sources
By Pamela Barbaglia, Olivia Oran and Arno Schuetze LONDON/NEW YORK/FRANKFURT (Reuters) – Investment bank Lazard is working with Sanofi’s management…
November 20, 2015
Sanofi and AstraZeneca to share compound libraries
Sanofi and AstraZeneca have announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries.
November 19, 2015
Sanofi CEO: Health must be part of the Climate debate
Sanofi will participate to Solutions COP21, the United Nations conference on climate change, as an official partner, a public exhibition in Paris.
November 18, 2015
UK cost watchdog turns down Amgen’s new cholesterol drug
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.
November 18, 2015
French academic Xavier Darcos to preside Sanofi
Sanofi has appointed Xavier Darcos as President of the Sanofi Espoir Foundation, who succeeds Jean-François Dehecq. Under Dehecq’s Presidency, According to the…
November 9, 2015
Sanofi’s and Regeneron’s study shows improvements in signs and symptoms of rheumatoid arthritis
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…
November 6, 2015
Sanofi and Lexicon to develop sotagliflozin (for diabetics)
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
November 5, 2015
Sanofi and Hanmi in $3.5B license agreement (developing diabetes treatments)
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.